List of Excipients in Branded Drug CYCLOPHOSPHAMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	AMMONIA
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	BUTYL ALCOHOL
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	FERROSOFERRIC OXIDE
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	GELATIN

Generic Drugs Containing CYCLOPHOSPHAMIDE

Company	Ingredient	NDC	Excipient
Sagent Pharmaceuticals	cyclophosphamide	25021-247	MANNITOL
Sagent Pharmaceuticals	cyclophosphamide	25021-247	WATER
XGen Pharmaceuticals DJB Inc	cyclophosphamide	39822-0255	MANNITOL
ANI Pharmaceuticals Inc	cyclophosphamide	43975-308	ALCOHOL
ANI Pharmaceuticals Inc	cyclophosphamide	43975-308	BUTYL ALCOHOL
ANI Pharmaceuticals Inc	cyclophosphamide	43975-308	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in CYCLOPHOSPHAMIDE?

# Of NDCs	Excipient
1	ACACIA
3	ALCOHOL
2	AMMONIA
4	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10

Excipient Strategy and Commercial Opportunities for Cyclophosphamide

Last updated: February 26, 2026

What Are the Current Excipient Formulations of Cyclophosphamide?

Cyclophosphamide is an alkylating agent used primarily in chemotherapy. Its formulation depends on the route of administration and intended stability. Commercially available formulations include:

• Intravenous (IV) formulations: Acidic aqueous solutions with sodium chloride or dextrose. These often contain excipients like sodium hydroxide or hydrochloric acid for pH adjustment.
• Oral tablets: Enteric-coated or non-coated tablets with excipients such as microcrystalline cellulose, magnesium stearate, and croscarmellose sodium.
• Lyophilized powders: Stabilized with excipients including mannitol and leucine for reconstitution stability.

Current formulations focus on pH stability, solubility, and minimizing degradation, especially in aqueous environments.

What Are the Key Challenges and Opportunities in Excipient Selection?

Stability and Compatibility

Cyclophosphamide degrades under specific conditions, with hydrolysis and thermal decomposition common. Excipients must preserve drug stability without accelerating degradation.

• Opportunity: Develop new excipients or formulations that enhance stability, reducing shelf-life variability and supporting commercial scalability.

Patient Tolerance and Safety

Some excipients (e.g., sodium salts, certain stabilizers) can cause hypersensitivity or adverse reactions.

• Opportunity: Formulate with excipients that improve tolerability, enabling broader patient demographics and reducing side effects related to excipient sensitivity.

Formulation Innovation

There is an industry shift toward targeted delivery and controlled-release formulations.

• Opportunity: Incorporate excipients like biodegradable polymers or lipid-based carriers for sustained or targeted release, expanding application scope and dosing flexibility.

How Could Excipient Innovations Lead to Competitive Advantages?

Improved Stability Profiles

Enhanced excipient formulations can increase shelf life, decrease waste, and streamline logistics.

Enhanced Patient Compliance

Oral formulations with gentler excipients can reduce gastrointestinal irritation, increasing adherence.

Market Expansion

Innovative excipient combinations facilitating oral or injectable forms with superior pharmacokinetics can open new markets, especially in regions demanding oral chemotherapies.

Intellectual Property

Novel excipient systems or combinations can generate patent opportunities, creating barriers to generic competition.

What Are Commercial Strategies for Excipient Development?

Partnerships with Excipient Suppliers

Collaborate with companies specializing in high-purity excipients or novel excipient platforms.

Investment in Formulation R&D

Focus on stability enhancements, tolerability, and controlled-release delivery mechanisms.

Regulatory Navigation

Obtain approval for new excipient systems via FDA or EMA pathways, emphasizing safety profiles and stability data.

Market Differentiation

Position formulations as safer, more effective, or more patient-friendly through clinical trials and marketing.

What Are Regulatory and Intellectual Property Considerations?

• Regulatory: New excipients or formulations may require extensive safety and stability studies. Regulatory agencies demand evidence supporting excipient safety and compatibility.
• Intellectual Property: Patents can cover novel excipient combinations, formulation processes, or delivery systems, protecting innovation and market exclusivity.

Summary Table: Excipient Strategies for Cyclophosphamide

Strategy	Benefits	Challenges	Commercial Opportunity
Stabilization via novel excipients	Extends shelf life, reduces degradation	Requires thorough safety and stability testing	Patents, market differentiation
Tolerability improvements	Broadens patient demographics, reduces side effects	Balancing excipient effectiveness and safety	Market expansion, premium formulations
Controlled-release systems	Enables dosing flexibility, targeted delivery	Complex formulation and regulatory approval	New indications, patent potential

Key Takeaways

• Cyclophosphamide formulations depend on excipient stability, compatibility, and patient tolerability.
• Development of novel excipients can improve shelf life, efficacy, and patient compliance.
• Formulation innovation supports market expansion, especially into outpatient and targeted therapies.
• Regulatory pathways demand comprehensive safety and stability data for new excipient systems.
• Strategic partnerships and patent protection drive competitive advantage.

FAQs

1. Are there any FDA-approved excipients specifically for cyclophosphamide formulations?
No, existing formulations often use common excipients. Innovation in excipient systems involves developing new carriers or stabilizers, which require regulatory approval.

2. What excipient types are most suited for improving cyclophosphamide stability?
Buffers and stabilizers such as antioxidants (e.g., EDTA) or pH adjusters can mitigate hydrolysis. Lipid-based excipients may support controlled release.

3. Could novel excipients reduce manufacturing costs?
Potentially. Stabilizing formulations that extend shelf life and reduce degradation can lower storage and waste costs, though initial R&D investments are necessary.

4. How does excipient choice influence market approval for new cyclophosphamide formulations?
Excipients must be recognized as safe (Generally Recognized As Safe - GRAS) or approved by regulatory agencies. Novel excipients require extensive safety documentation.

5. Is there scope for personalized cyclophosphamide formulations?
Yes, tailored excipient systems can optimize pharmacokinetics for individual patients, enabling personalized medicine approaches, especially with controlled-release systems.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipient Classification for Drugs. FDA.
[2] Smith, J. D., & Lee, A. (2020). Advances in chemotherapeutic formulations. International Journal of Pharmaceutical Sciences, 55(4), 789-802.
[3] European Medicines Agency. (2021). Guideline on the Quality of Modified Release Formulations. EMA.